HC Wainwright Raises Atossa Therapeutics (NASDAQ:ATOS) Price Target to $6.00

Atossa Therapeutics (NASDAQ:ATOS – Free Report) had its target price upped by HC Wainwright from $4.00 to $6.00 in a research report released on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Atossa Therapeutics’ Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings […]

Related Keywords

Jonathan Finn ,Atossa Therapeutics Inc ,Securities Exchange Commission ,Atossa Therapeutics Company Profile ,Connor Clark Lunn Investment Management Ltd ,Vanguard Group Inc ,Atossa Therapeutics ,Free Report ,Get Free Report ,Director Jonathan Finn ,Exchange Commission ,Lunn Investment Management ,Vanguard Group ,Atossa Therapeutics Daily ,